НовостиBenzingaOppenheimer Initiates Coverage On Retension Pharmaceuticals with Outperform Rating, Announces Price Target of $50 Oppenheimer Initiates Coverage On Retension Pharmaceuticals with Outperform Rating, Announces Price Target of $50 Benzinga 2026.11.03 17:13 (GMT+0) Открыть на Benzinga Другие новости